ERBB4 mutation analysis: Emerging molecular target for melanoma treatment

Methods in Molecular Biology

Volumn 1102, Issue , 2014, Pages 461-480

  Lau, Christopher ^a   Killian, Keith J ^a   Samuels, Yardena ^b   Rudloff, Udo ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

DNA isolation; ERBB4 gene; Genomic landscape; Marker predictive for treatment; Metastatic melanoma; Mutation validation; Sanger sequencing; Somatic mutations; Treatment target

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 4; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; PICTILISIB; PROTEIN TYROSINE KINASE; TRAMETINIB; VEMURAFENIB;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOSENSITIVITY; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EXON; GENETIC ANALYSIS; GENOTYPE; HUMAN; HUMAN TISSUE; KNOWLEDGE; METASTATIC MELANOMA; MISSENSE MUTATION; MOLECULARLY TARGETED THERAPY; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; ONCOGENE; PATIENT SELECTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SOMATIC MUTATION; TISSUE SECTION;

BASE SEQUENCE; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; ELECTROPHORESIS, CAPILLARY; EXONS; HUMANS; MELANOMA; MOLECULAR SEQUENCE DATA; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84891805814     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-727-3_24     Document Type: Article

References (37)

1. Greenman C et al (2007) Patterns of somatic mutation in human cancer genomes. Nature 446(7132):153-158
2. Pleasance ED et al (2010) A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463(7278): 191-196
3. Drobetsky EA, Grosovsky AJ, Glickman BW (1987) The specificity of UV-induced mutations at an endogenous locus in mammalian cells. Proc Natl Acad Sci U S A 84(24): 9103-9107
4. Berger MF et al (2012) Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 485(7399):502-506
5. Curtin JA et al (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353(20):2135-2147
6. Turajlic S et al (2012) Whole genome sequencing of matched primary and metastatic acral melanomas. Genome Res 22(2):196-207
7. Walia V et al (2012) Delving into somatic variation in sporadic melanoma. Pigment Cell Melanoma Res 25(2):155-170
8. Prickett TD et al (2009) Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet 41(10):1127-1132
9. Mok TS et al (2009) Gefi tinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10):947-957
10. Rosell R et al (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361(10):958-967
11. Solomon DA et al (2008) Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma. Cancer Res 68(24):10300-10306
12. Palavalli LH et al (2009) Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma. Nat Genet 41(5):518-520
13. Wei X et al (2010) Mutational and functional analysis reveals ADAMTS18 metalloproteinase as a novel driver in melanoma. Mol Cancer Res 8(11):1513-1525
14. Wei X et al (2011) Analysis of the disintegrinmetalloproteinases family reveals ADAM29 and ADAM7 are often mutated in melanoma. Hum Mutat 32(6):E2148-E2175
15. Prickett TD et al (2011) Exon capture analysis of G protein-coupled receptors identifi es activating mutations in GRM3 in melanoma. Nat Genet 43(11):1119-1126
16. Prickett TD, Samuels Y (2012) Molecular pathways: Dysregulated glutamatergic signaling pathways in cancer. Clin Cancer Res 18(16):4240-4246
17. Wei X et al (2011) Exome sequencing identifi es GRIN2A as frequently mutated in melanoma. Nat Genet 43(5):442-446
18. Hahn CG et al (2006) Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat Med 12(7):824-828
19. Garcia RA, Vasudevan K, Buonanno A (2000) The neuregulin receptor ErbB-4 interacts with PDZ-containing proteins at neuronal synapses. Proc Natl Acad Sci U S A 97(7):3596-3601
20. Delint-Ramirez I et al (2010) In vivo composition of NMDA receptor signaling complexes differs between membrane subdomains and is modulated by PSD-95 and PSD-93. J Neurosci 30(24):8162-8170
21. D'Onofrio M et al (2003) Pharmacological blockade of mGlu2/3 metabotropic glutamate receptors reduces cell proliferation in cultured human glioma cells. J Neurochem 84(6):1288-1295
22. Namkoong J et al (2007) Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma. Cancer Res 67(5): 2298-2305
23. Yip D et al (2009) A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma. Clin Cancer Res 15(11):3896-3902
24. Wood LD et al (2007) The genomic landscapes of human breast and colorectal cancers. Science 318(5853):1108-1113
25. Fine B et al (2009) Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a. Science 325(5945):1261-1265
26. Colombino M et al (2012) BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 30(20):2522-2529
27. Chapman PB et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26): 2507-2516
28. Flaherty KT et al (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367(2):107-114
29. Guo J et al (2011) Phase II, open-label, singlearm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplifi cation. J Clin Oncol 29(21): 2904-2909
30. Samuels Y, Waldman T (2010) Oncogenic mutations of PIK3CA in human cancers. Curr Top Microbiol Immunol 347:21-41
31. Turke AB, Engelman JA (2010) PIKing the right patient. Clin Cancer Res 16(14):3523-3525
32. Dutton-Regester K et al (2012) A highthroughput panel for identifying clinically relevant mutation profi les in melanoma. Mol Cancer Ther 11(4):888-897
33. Wagle N et al (2011) Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 29(22): 3085-3096
34. Molina-Vila MA et al (2009) Screening for EGFR mutations in lung cancer. Discov Med 8(43):181-184
35. Rudloff U, Samuels Y (2010) A growing family: Adding mutated Erbb4 as a novel cancer target. Cell Cycle 9(8):1487-1503
36. Garrett TP et al (2002) Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 110(6): 763-773
37. Ogiso H et al (2002) Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110(6): 775-787